Nearly 600 teenagers ages 12 to 17 years who suffered an average of two to eight migraines per month participated in the trial, which consisted of a 12-week, single-blind, run-in phase followed by a 12-week, double-blind, treatment phase. In both phases, patients received either a placebo or one of three combinations: sumatriptan 10 mg/naproxen sodium 60 mg; sumatriptan 30 mg/naproxen 180 mg; or sumatriptan 85 mg/naproxen 500 mg.
The study found that all three doses were effective and well tolerated among patients. In particular, the 10/60-mg dose was more effective for shorter-duration headaches and younger teenagers, while the 85/500-mg dose proved more effective for recurring migraines and older teenagers.
Related Articles on Pain Management:
New Treatment Uses IV Injections for Severe Migraines
CMS Proposed Cutoff of TENS Coverage Draws Scrutiny from Congressman
Hospira Recalls Opioid Cartridges
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
